NFSG
SKYE icon

Newbridge Financial Services Group’s Skye Bioscience SKYE Stock Holding History

Newbridge Financial Services Group’s Portfolio SKYE Stock Details SKYE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1 Sell
1
-17
-94% -$14 ﹤0.01% 1181
2025
Q4 		$13 Hold
18
– – ﹤0.01% 1169
2025
Q3 		$71 Hold
18
– – ﹤0.01% 1265
2025
Q2 		$75 Hold
18
– – ﹤0.01% 1289
2025
Q1 		$29 Hold
18
– – ﹤0.01% 1030
2024
Q4 		$51 Hold
18
– – ﹤0.01% 1118
2024
Q3 		$70 Hold
18
– – ﹤0.01% 643
2024
Q2 		$144 Buy
+18
New +$214 ﹤0.01% 1054

Other funds holding SKYE

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Newbridge Financial Services Group's SKYE Position: Q1 2026 in Review

Newbridge Financial Services Group reduced its Skye Bioscience (SKYE) stake by 94% in Q1 2026, selling an estimated $14 and leaving 1 share worth $1. The position accounts for ﹤0.01% of the portfolio, ranked #1181.

Newbridge Financial Services Group first reported a position in SKYE in Q2 2024 and has held it in 8 quarters since. The position peaked at $144 in Q2 2024. 39 funds tracked by Wall St. Rank hold SKYE as of Q1 2026.

  • Newbridge Financial Services Group held 1 share of Skye Bioscience worth $1 as of Q1 2026.
  • Newbridge Financial Services Group sold 17 Skye Bioscience shares in Q1 2026, an estimated $14.
  • Skye Bioscience made up ﹤0.01% of Newbridge Financial Services Group's portfolio in Q1 2026, its #1181 holding.
  • Newbridge Financial Services Group first reported a position in Skye Bioscience in Q2 2024 and has held it in 8 quarters since.
  • Newbridge Financial Services Group's Skye Bioscience position peaked at $144 in Q2 2024.
  • 39 funds tracked by Wall St. Rank held Skye Bioscience as of Q1 2026.

Based on Newbridge Financial Services Group's 13F filing for Q1 2026, filed 5 May 2026.